FMTX - Forma's olutasidenib shows positive action in mid-stage leukemia study

Forma Therapeutics Holdings (FMTX) announces positive preliminary data from a planned interim analysis of a Phase 2 clinical trial evaluating olutasidenib (FT-2102) in patients with isocitrate dehydrogenase 1 ((IDH1)) mutation-positive acute myeloid leukemia ((AML)).Patients receiving olutasidenib monotherapy showed a 33.3% composite complete remission rate (30% CR plus 3% CR with partial hematologic recovery).Median duration of response has not been reached but a sensitivity analysis indicated that it could be 13.8 months.The tolerability profiles was favorable. The most common adverse events were nausea, constipation, increased white blood cell count, decreased red blood cell count, fever, febrile neutropenia and fatigue.Additional data will be presented at an upcoming medical conference.Olutasidenib is an orally available small molecule IDH1 inhibitor. IDH1 mutations occur early in tumor formation and persist throughout progression from a neural stem or progenitor cell.

For further details see:

Forma's olutasidenib shows positive action in mid-stage leukemia study